Skip to main content
. 2019 Oct 21;9(26):8253–8265. doi: 10.7150/thno.37351

Figure 1.

Figure 1

Serum IL-27 negatively correlates with disease activity in patients with Sjögren's syndrome. (A, B) IL-27 mRNA in PBMCs (A) and serum IL-27 (B) in patients with Sjögren's syndrome (SS) (n=30) compared with those of healthy controls (HC) (n=30). (C,D) Expression of IL-27 receptors, gp130 mRNA (C) and IL-27RαmRNA (D), were detected in PBMC from SS patients (n=5) and HC. (n=5) (E) Serum IL-27 was assessed according the European League Against Rheumatism (EULAR) Sjögren's syndrome Disease Activity Index (ESSDAI) scores. (F) Serum IL-27 was compared between SS patients with (n=14) and without anti-SSA antibody (n=15). (G) Correlation of serum IL-27 and IgG was analyzed. (H) Percentages of Th17 and Treg cells in SS patients (n=15) and HC (n=15) were shown. (I, J) Serum TGF-β (i) and IL-17A (j) in SS patients and HC were detected. (K, L) Correlations of IL-27 and Treg and Th17 cells were evaluated. Data were based on three independent experiments. Data are presented as mean±SEM. *, p<0.05, **, p<0.01, ***, p<0.001.